Veracyte (VCYT) Misses Q1 EPS by 2c, Beats on Revenues; Raises FY18 Revenue Outlook
Get Alerts VCYT Hot Sheet
Join SI Premium – FREE
Veracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $20 million versus the consensus estimate of $18.02 million.
First Quarter 2018 Financial Results
For the first quarter of 2018, as compared to the first quarter of 2017:
- Revenue was $20.0 million, an increase of 22%;
- Genomic Volume was 6,864, an increase of 18%;
- Gross Margin was 61%, a decline of 1%;
- Operating Expenses, Excluding Cost of Revenue were $21.1 million, an increase of 20%;
- Net Loss and Comprehensive Loss was ($9.2) million, an increase of 12%;
- Basic and Diluted Net Loss Per Common Share was ($0.27), an increase of 13%;
- Cash Burn1 was $7.6 million, an improvement of 8%; and
- Cash and Cash Equivalents was $27.2 million at March 31, 2018.
Updated 2018 Financial Outlook
Veracyte is increasing its 2018 annual revenue guidance to $83 million to $86 million, from its prior guidance of $81 million to $83 million. The company reiterates its annual cash burn guidance of $18 million to $22 million.
GUIDANCE:
Veracyte sees FY2018 revenue of $83-86 billion, versus the consensus of $81.64 billion.
For earnings history and earnings-related data on Veracyte (VCYT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- SPS Commerce (SPSC) Tops Q1 EPS by 12c
- Alphabet (GOOG) Tops Q1 EPS by 38c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!